28th July 2025
Cumulus Neuroscience Presents Data at AAIC 2025 Annual Meeting and Technology and Dementia Preconference
18th July 2025
Cumulus Neuroscience Announces Publication of Data and Upcoming Data Presentation at AAIC 2025 Technology and Dementia Preconference and Annual Meeting
29th May 2025
NeuLogiq® Platform Confirms Electrophysiological Marker of Target Engagement in Patients with Major Depressive Disorder
29th April 2025
Breaking new ground in mental health research: Oxford University, Boehringer Ingelheim and Cumulus Neuroscience launch first of its kind study investigating the day-to-day experience of patients with psychiatric disorders
1st August 2024
Cumulus Neuroscience Presents Data at AAIC 2024 Annual Meeting and Technology and Dementia Preconference
17th July 2024
Cumulus Neuroscience to Present Data at AAIC 2024 Annual Meeting and Technology and Dementia Preconference
11th July 2024
Cumulus Neuroscience to Join Bio-Hermes 2 Study with Funding from the Innovate UK Small Business Research Initiative (SBRI) Dementia Mission Project
11th June 2024
Cumulus Neuroscience to Partner with The Digital Medicine Society (DiMe) to Drive Adoption of Digital Endpoints in Clinical Trials
22nd March 2024
Cumulus Neuroscience Receives Innovate UK Small Business Research Initiative (SBRI) Grant Focused on Clinical Biomarker Tools and Technologies for Dementia
21st March 2024
Cumulus Neuroscience Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2024
14th March 2024
Cumulus Neuroscience Announces First Patient Enrolled in AccelADx Electroencephalogram (EEG) Study for Early Detection of Alzheimer's Dementia
7th February 2024
Cumulus Neuroscience Named GOOD DESIGN® Award Winner for Cutting-Edge EEG Headset
17th July 2023
Cumulus Neuroscience Presents Data at AAIC 2023 Annual Meeting and Technology and Dementia Preconference
13th July 2023
Cumulus Neuroscience Announces Research Collaboration with the Universities of Bath and Bristol on Development of Breakthrough Test for Early Detection of Alzheimer's Dementia
12th July 2023
Cumulus Neuroscience Presents Key Data at the 2023 ENCALS Annual Meeting on Patients with Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD)
11th July 2023
Cumulus Neuroscience to Present Data at AAIC 2023 Annual Meeting and Technology and Dementia Preconference
6th July 2023
Cumulus Neuroscience to Present Data at 2023 ENCALS Annual Meeting on Patients with Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD)
31st May 2023
Cumulus Neuroscience Completes Patient Enrollment for Pivotal CNS-101 Early-stage Alzheimer’s Dementia Validation Trial
4th May 2023
Cumulus Neuroscience Receives FDA 510(k) Clearance for Award-Winning, First-In-Class Neurophysiology Platform for At-Home Use
2nd May 2023
Cumulus Neuroscience Appoints Tina Sampath as Chief Commercial Officer, Strengthening Leadership Team Amid Continued Company Growth
27th April 2023
Cumulus Neuroscience Lands Coveted iF Design and Red Dot Awards for Innovative At-Home EEG Device
11th April 2023
Cumulus Neuroscience Expands Development Support of Novel Precision CNS Therapeutics
1st February 2023
Cumulus Neuroscience Expands Executive Team, Supporting Biopharma Business Growth
21st September 2022
Cumulus Neuroscience appoints digital health and pharmaceutical executive Aman Bhatti, MD as Chief Executive Officer
10th August 2022
New study highlights superior efficacy of at-home dry EEG assessment compared to lab-based monitoring
25th May 2022
Cumulus Neuroscience commences clinical studies of digital biomarker platform in degenerative neurological diseases
12th November 2021
Cumulus’ CSO appears at FT Pharma conference to discuss new dementia treatments
25th June 2021
Frontiers in Psychiatry paper explores feasibility of at-home EEG assessment
4th May 2021
Cumulus Neuroscience Announces £6 million Funding Round Led by the Dementia Discovery Fund and joined by LifeArc and UK Future Fund
5th April 2021
Cumulus Neuroscience receives £1.8m Biomedical Catalyst grant to expand CNS biomarker platform
1st March 2021
Cumulus Neuroscience adds Winterlight Labs’ speech analytics technology to its integrated physiological and digital biomarker platform for CNS disorders
5th January 2021
Cumulus Neuroscience licences P1vital Product’s facial expression recognition software for use in CNS trials